GRI Bio (NASDAQ:GRI) Given New $27.00 Price Target at Ascendiant Capital Markets

GRI Bio (NASDAQ:GRI) had its price objective decreased by Ascendiant Capital Markets from $32.00 to $27.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GRI Bio in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $27.00.

GRI Bio Stock Performance

Shares of GRI opened at $1.65 on Friday. The firm’s 50-day simple moving average is $1.71 and its two-hundred day simple moving average is $2.13. GRI Bio has a fifty-two week low of $1.36 and a fifty-two week high of $80.36. The stock has a market cap of $3.61 million, a PE ratio of -0.04 and a beta of -1.20.

GRI Bio (NASDAQ:GRI) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.28. Equities research analysts predict that GRI Bio will post -4.77 EPS for the current year.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.